A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

(2011) Gareth J Morgan et al.   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

(2011) Giovanni D'arena et al.   LEUKEMIA & LYMPHOMA

Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study

(2010) S. Y. Kristinsson et al.   BLOOD

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma

(2010) Sumit Madan et al.   MAYO CLINIC PROCEEDINGS

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations

(2009) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD